Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Zhang J-j, Sun W-j, Huang Z-x, Chen S-l, Zhong Y-p, Hu Y et al (2014) Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. World J Surg Oncol 12:1–4
2. Chilkulwar A, Miller A, Mewawalla P, Berteotti G, Kaminsky A, Sadhashiv S et al (2016) High serum free light chain concentration (> 1000 mg/dl) at the time of relapse to predict poor prognosis in multiple myeloma. J Clin Oncol 34(15suppl):8064
3. Singh G, Xu H (2021) Light chain predominant intact immunoglobulin monoclonal gammopathy disorders: shorter survival in light chain predominant multiple myelomas. Lab Med 52(4):390–398
4. Benson R, Nair SG, Narayanan G (2020) Early normalization of Free Light Chains predicts better outcomes in patients with multiple myeloma. Int J hematology-oncology stem cell Res 14(4):226–231
5. Huang ZQ, Kirk KA, Connelly KG, Sanders PW (1993) Bence Jones proteins bind to a common peptide segment of Tamm-Horsfall glycoprotein to promote heterotypic aggregation. J Clin Investig 92(6):2975–2983